by Medscape
Join Dr Lidia Schapira for Medscape InDiscussion: Breast Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/963162). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Language
🇺🇲
Publishing Since
3/15/2022
Email Addresses
1 available
Phone Numbers
0 available
July 14, 2022
<p>Drs Lidia Schapira and Norah Lynn Henry discuss adjuvant endocrine therapy.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969538). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update https://ascopubs.org/doi/10.1200/JCO.18.01160</p> <p>Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients With Breast Cancer https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30666-5/fulltext</p> <p>Acupuncture for Arthralgia-Induced by Aromatase Inhibitors in Patients With Breast Cancer: A Systematic Review and Meta-analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883140/</p> <p>Long-Term Results From a Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Early Stage Breast Cancer (S1200) https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.12018</p> <p>Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias https://academic.oup.com/jncics/article/5/2/pkab018/6130825</p> <p>Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341106/</p> <p>Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women With Breast Cancer https://maps.cancer.gov/overview/DCCPSGrants/abstract.jsp?applId=10337861&term=CA266012</p> <p>Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer https://academic.oup.com/oncolo/article/21/5/539/6401566?login=false</p> <p>Effect of a Switch of Aromatase Inhibitors on Musculoskeletal Symptoms in Postmenopausal Women With Hormone-Receptor-Positive Breast Cancer: The ATOLL (Articular Tolerance of Letrozole) Study https://pubmed.ncbi.nlm.nih.gov/20035381/</p> <p>Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment https://ascopubs.org/doi/full/10.1200/JCO.20.03375</p> <p>Cohort Study of Adherence to Adjuvant Endocrine Therapy, Breast Cancer Recurrence and Mortality https://www.nature.com/articles/bjc2013116</p> <p>Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493485/</p> <p>Caution: Vaginal Estradiol Appears to Be Contraindicated in Postmenopausal Women on Adjuvant Aromatase Inhibitors https://www.annalsofoncology.org/article/S0923-7534(19)57558-5/fulltext</p> <p>Management of Genitourinary Syndrome of Menopause in Breast Cancer Survivors: An Update https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894268/</p>
June 14, 2022
<p>Drs Lidia Schapira and Kevin Kalinsky discuss the RxPONDER trial and immunotherapy.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963171). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.</p> <p>21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer https://www.nejm.org/doi/10.1056/NEJMoa2108873</p> <p>Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457/</p> <p>Randomized Comparisons of Adjuvant Aromatase Inhibitor Exemestane Plus Ovarian Function Suppression vs Tamoxifen in Premenopausal Women With Hormone Receptor–Positive Early Breast Cancer: Update of the TEXT and SOFT Trials https://www.abstractsonline.com/pp8/#!/10462/presentation/645</p> <p>Breast Cancer Index https://www.breastcancerindex.com/</p> <p>Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768339/</p> <p>Continuous Versus Intermittent Extended Adjuvant Letrozole for Breast Cancer: Final Results of Randomized Phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy https://linkinghub.elsevier.com/retrieve/pii/S0923-7534(21)02492-3</p> <p>Event-free Survival With Pembrolizumab in Early Triple-Negative Breast Cancer https://www.nejm.org/doi/10.1056/NEJMoa2112651</p>
May 17, 2022
<p>Drs Lidia Schapira and Kathryn Ruddy discuss treatment and follow-up care for premenopausal women with breast cancer.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963169). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p><em>MutYH</em> Mutation Carriers Have Increased Breast Cancer Risk https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.26506</p> <p>Kathryn J. Ruddy, MD, MPH Biography https://www.mayoclinic.org/biographies/ruddy-kathryn-j-m-d/BIO-20055748?_escaped_fragment_=&p=1</p> <p>Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1804710</p> <p>About Oncotype DX Breast DCIS Score https://www.oncotypeiq.com/en-US/breast-cancer/healthcare-professionals/oncotype-dx-breast-dcis-score/about-the-test</p> <p>Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405231/</p> <p>Adjuvant Ovarian Suppression in Premenopausal Breast Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa1412379</p> <p>Who Are the Women Who Enrolled in the POSITIVE Trial: A Global Study to Support Young Hormone Receptor Positive Breast Cancer Survivors Desiring Pregnancy https://www.sciencedirect.com/science/article/pii/S096097762100429X</p> <p>Pregnancy After Breast Cancer https://www.cancer.org/cancer/breast-cancer/living-as-a-breast-cancer-survivor/pregnancy-after-breast-cancer.html</p> <p>Pragmatic Cluster Randomized Trial to Evaluate Effectiveness and Implementation of Enhanced EHR-Facilitated Cancer Symptom Control (E2C2) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275300/</p>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.